Petrelintide is under clinical development by Zealand Pharma and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Petrelintide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Petrelintide overview

ZP-8396 is under development for the treatment of obesity and type 2 diabetes. It is a long acting amylin analogue. It is administered through subcutaneous and intravenous routes.

Zealand Pharma overview

Zealand Pharma (Zealand) is a biotechnology company that discovers and develops peptide-based medicines. The company’s pipeline products include liraglutide, a long-acting GLP-2 analog in development for the treatment of short bowel syndrome; dasiglucagon for congenital hyperinsulinism and bi-hormonal artificial pancreas systems; survodutide (BI 456906) treats obesity and nonalcoholic steatohepatitis; ZP8396 for overweight and obesity; dapiglutide for obesity. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. Zealand is headquartered in Soeborg, Denmark.

For a complete picture of Petrelintide’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.